Loan License vs Own Manufacturing License in India: Which Route Is Right for Your Medical Device Business?

One of the most consequential decisions a Medical Device company faces when entering the Indian manufacturing landscape is whether to establish its own licensed manufacturing facility or to operate under a loan license arrangement. Both routes are fully legitimate under India’s Medical Devices Rules, 2017 (MDR 2017), and each carry distinct regulatory, financial, and operational implications.

Before applying for either a manufacturing license or a loan license, it is important to understand that the eligibility criteria and Regulatory expectations differ for each pathway.

This article provides a comprehensive, side-by-side analysis of the two models to help companies make an informed decision aligned with their business strategy, product pipeline, and long-term India ambitions.

Understanding the Two Models

Own Manufacturing License

A Manufacturing License authorizes a company to manufacture Medical Devices at its own approved facility, in compliance with the requirements of India’s Medical Devices Rules, 2017 (MDR 2017). Under this model, the company is responsible for establishing and maintaining its own infrastructure, quality management system, and Regulatory Compliance, and it manufactures and markets the product under its own name.

A manufacturing license — applied for through MD-3 (Class A/B) or MD-7 (Class C/D) — means your company establishes and operates its own manufacturing facility in India. The license is held in your company’s name, and you are fully responsible for the facility, the manufacturing process, the quality management system, and regulatory compliance.

Loan License

A Loan License permits a company to manufacture its Medical Devices using the facilities of another licensed manufacturer, while marketing the products under its own brand. This model is particularly useful for startups, importers, healthcare companies, and brand owners who want market access without investing in their own manufacturing infrastructure.

Simply put:

• Company A owns a licensed manufacturing facility.
• Company B intends to sell Medical Devices under its own brand name.
• Instead of setting up a factory, Company B uses Company A’s facility for production.
• Company B obtains a Loan License from CDSCO to operate under this arrangement.

A loan license — applied for through MD-4 (Class A/B) or MD-8 (Class C/D) — allows your company to manufacture products using the premises, plant, equipment, and technical staff of a licensed manufacturer (the licensor). You hold the Regulatory license in your own name and take responsibility for the product, but the physical manufacturing is carried out at a third-party facility.

Comparative Analysis

Table1

When the Loan License Route Makes Strategic Sense

The loan license model is particularly well suited to the following scenarios:

• Market entry testing: A foreign MedTech company wants to manufacture and sell in India before committing to a greenfield facility investment
• Startup capital conservation: An early-stage Indian MedTech company aims to launch a product while preserving capital for R&D and commercialisation
• Bridge strategy: A company plans to establish its own facility long-term but needs to generate revenue while construction and approvals are underway
• Low-volume or niche products: Products with limited demand that do not justify the capital investment required for a dedicated manufacturing facility
• Contract manufacturing partnerships: Situations where an established relationship with a licensed manufacturer ensures quality, reliability, and faster execution

A well-structured loan license agreement is critical. The agreement must clearly define product ownership, batch release authority, quality responsibilities, IP protection, exclusivity terms, and dispute resolution mechanisms. CDSCO expects this agreement to be robust and legally sound.

Regulatory Considerations Specific to Loan Licenses

Several Regulatory nuances are important to understand before choosing the loan license route:

• The loan licensee holds the license and bears full Regulatory responsibility for product safety and compliance — including post-market surveillance and vigilance reporting
• The licensor’s manufacturing license must cover the same device class and type of product being manufactured under the loan arrangement
• CDSCO or the SLA will inspect both the licensor’s facility and verify the loan agreement during the application process
• Any change in the licensor (i.e., switching to a different manufacturing partner) requires regulatory notification and may require a fresh application
• The loan licensee’s name and address must appear on the product label alongside the licensor’s site details

Transitioning from Loan License to Own License

Many successful Indian Medtech companies begin with a loan license and transition to their own manufacturing facility once revenue and volume justify the investment. This is a well-recognised strategic pathway. Key considerations when planning this transition:

• Begin facility planning and site selection early — approval timelines for own manufacturing licenses are 12–18 months for Class C/D
• Use the loan license period to build your QMS, technical team, and Regulatory track record
• Maintain good relationships with your licensor — you may need their capacity while your own facility is being approved
• Budget for parallel running costs: both the loan license and the own facility approval process overlap during the transition period

Conclusion

The decision between a loan license and an own manufacturing license is not binary or permanent it is a strategic choice that should evolve with the company’s growth.

• For companies entering the Indian market, a loan license offers a faster, lower-risk pathway with reduced upfront investment.
• For companies with established demand and long-term strategic commitment, an own manufacturing license provides greater control, scalability, and stronger IP protection.

A phased approach—starting with a loan license and transitioning to an owned facility—is often the most practical and commercially efficient pathway for many MedTech companies.